Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: A randomized, open-label, crossover study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 11, 2000, Pages 789-797

  Malacco, Ettore ^a   Piazza, Simona ^a   Meroni, Rachele ^a   Milanesi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Hypertension; Irbesartan; Valsartan

Indexed keywords

IRBESARTAN; VALSARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0033749162     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)90005-5     Document Type: Article

References (23)

1. Franz Volhard Lecture. Renin-angiotensin system: A dual tissue and hormonal system for cardiovascular control
2. Angiotensin receptors and their antagonists
3. Signal transduction revisited: Recent developments in angiotensin II signaling in the cardiovascular system
4. Angiotensin II-receptors
5. Throphic actions by angiotensin II-receptors
6. The renin-angiotensin system and its receptors
7. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
8. Angiotensin II receptor antagonists
9. 1-receptor subtype
10. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist
11. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
12. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
13. 1 receptors
14. Pharmacokinetics, disposition and biotransformation of (14C)-radiolabelled valsartan in healthy male volunteers after a single oral dose
15. 1 subtype angiotensin II receptor antagonist
16. 1 receptor antagonist irbesartan in hypertension
17. The new angiotensin II receptor antagonist, irbesartan. Pharmacokinetic and pharmacodynamic considerations
18. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements
19. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines Sub-committee of the World Health Organization
20. Blood pressure reduction and end-organ damage in hypertension
21. Troughpeak ratio of the blood pressure response to dihydropyridine calcium antagonists
22. 'Smoothness index' but not T/P ratio estimates balanced 24-h blood pressure control and predicts regression of organ damage by antihypertensive treatment